Polaris Pharmaceuticals Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Polaris Pharmaceuticals's estimated annual revenue is currently $6.8M per year.(i)
  • Polaris Pharmaceuticals's estimated revenue per employee is $201,000

Employee Data

  • Polaris Pharmaceuticals has 34 Employees.(i)
  • Polaris Pharmaceuticals grew their employee count by -6% last year.

Polaris Pharmaceuticals's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
EVP Medical AffairsReveal Email/Phone
3
VP Clinical AffairsReveal Email/Phone
4
SVP Research & DevelopmentReveal Email/Phone
5
Head Regulatory AffairsReveal Email/Phone
6
Director FacilitiesReveal Email/Phone
7
Associate Director QCReveal Email/Phone
8
Director, Environmental Health Safety Reveal Email/Phone
9
Associate Director, PharmacovigilanceReveal Email/Phone
10
Senior Clinical Trial ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$102.7M51125%N/AN/A
#2
$0.4M20%N/AN/A
#3
$38.6M1923%N/AN/A
#4
$35M1272%$62.5MN/A
#5
$36.6M18218%N/AN/A
#6
$131.9M656-3%N/AN/A
#7
$133.5M664N/AN/AN/A
#8
$72.8M362-4%N/AN/A
#9
$551.9M1716-2%N/AN/A
#10
$11.7M5812%N/AN/A
Add Company

What Is Polaris Pharmaceuticals?

Polaris Group, a privately held multinational biopharmaceutical drug company, specializes in the research and development of protein drugs to treat cancer and other debilitating diseases in humans. Polaris' lead project is ADI-PEG 20, a biotherapeutic agent that is in advanced clinical development for the treatment of hepatocellular carcinoma and metastatic melanoma. Polaris is collaborating with EnzymeRx in the development of Uricase-PEG 20 for the treatment of gout, tumor lysis syndrome, and other diseases related to hyperuricemia. Polaris is also researching and developing other biotherapeutic agents and has a small molecule drug program. The latter utilizes a rational structure-based approach for the design of novel compounds that inhibit the biological function of cancer-related protein targets.

keywords:N/A

N/A

Total Funding

34

Number of Employees

$6.8M

Revenue (est)

-6%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.3M34-3%N/A
#2
$8.5M34-8%N/A
#3
$2.6M3431%$18M
#4
$3.9M34N/AN/A
#5
$5.7M34N/AN/A